Precision medicine for slow-growing mastocytosis
Part of Cancer, Immune system & allergy clinical trials.
This study looks at people with a slow-growing type of mast cell disease called indolent systemic mastocytosis. The goal is to better understand the condition and how to manage it, using your genetic information to guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have indolent (slow-growing) systemic mastocytosis as diagnosed by your doctor.
- You are not diagnosed with the advanced (more aggressive) form of systemic mastocytosis.
- Your current mast cell medications have been stable for at least 2 weeks before starting.
- You have not had strong treatments like chemotherapy or interferon in the past 4 weeks.
- You are generally able to care for yourself and do daily activities (performance status 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for a specific genetic change (KIT-D816V mutation) in the blood of adults with mast cell disorders—conditions where immune cells called mast cells cause allergic-like reactions. Understanding this mutation may help doctors better diagnose and treat your condition.
This study is observing adults with indolent systemic mastocytosis (ISM) who are already receiving or planning to start symptom treatments or the drug avapritinib. It aims to learn more about how these treatments work in real life.
This study looks at how avapritinib works in people with indolent systemic mastocytosis whose symptoms are not well controlled by other treatments. You will take the drug as part of your usual care, and researchers will collect information to see how well it helps.
This trial tests BLU-263, a study medicine, against placebo (inactive treatment) to see if it improves symptoms in people with indolent systemic mastocytosis. It also checks safety and how well the dose is tolerated before and during treatment.
This study provides access to bezuclastinib, an oral medication, for people with advanced systemic mastocytosis whose current treatment isn't working well enough. The goal is to see if it can help control the disease when other options have not been effective.
This study looks at what causes mast cells to grow too much in people with mastocytosis. It may help researchers find better ways to diagnose or treat this condition. You can take part in person or by telehealth.
Hear when a new Systemic Mastocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.